Sequana Medical Announces Unconditional IDE Approval from U.S. FDA to Start alfapump® Pivotal Study (POSEIDON)

by NASDAQ Market News June 4, 2019

NASDAQ Market News
Click here to email author

OV’s method can predict if neoadjuvant treatment with doxorubicin in breast cancer will be successful, data published in ASCO journal

$11 million grant to study life-threatening blood clots in trauma patients

Ads